TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Short Interest Update

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 69,700 shares, a drop of 19.5% from the March 31st total of 86,600 shares. Based on an average daily volume of 31,200 shares, the short-interest ratio is currently 2.2 days. Approximately 2.8% of the company’s stock are short sold.

TFF Pharmaceuticals Price Performance

Shares of NASDAQ TFFP traded up $0.02 during midday trading on Tuesday, reaching $2.73. 54,781 shares of the company traded hands, compared to its average volume of 28,823. TFF Pharmaceuticals has a 52 week low of $2.51 and a 52 week high of $21.25. The stock has a 50-day moving average price of $5.70 and a 200 day moving average price of $6.53. The company has a market cap of $6.88 million, a price-to-earnings ratio of -0.22 and a beta of 1.29.

TFF Pharmaceuticals (NASDAQ:TFFP) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($2.00) by ($0.01). TFF Pharmaceuticals had a negative return on equity of 163.14% and a negative net margin of 2,897.95%. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.20 million. As a group, analysts expect that TFF Pharmaceuticals will post -7.28 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Roth Mkm decreased their price target on shares of TFF Pharmaceuticals from $56.00 to $44.00 and set a “buy” rating for the company in a research report on Thursday, March 28th.

Institutional Trading of TFF Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Worth Venture Partners LLC raised its holdings in TFF Pharmaceuticals by 66.2% during the 3rd quarter. Worth Venture Partners LLC now owns 646,832 shares of the company’s stock worth $226,000 after buying an additional 257,722 shares during the period. Westside Investment Management Inc. raised its holdings in TFF Pharmaceuticals by 382.1% during the 1st quarter. Westside Investment Management Inc. now owns 39,225 shares of the company’s stock worth $237,000 after buying an additional 31,089 shares during the period. Finally, AIGH Capital Management LLC grew its stake in TFF Pharmaceuticals by 70.7% during the 3rd quarter. AIGH Capital Management LLC now owns 2,655,235 shares of the company’s stock valued at $929,000 after acquiring an additional 1,099,709 shares in the last quarter. Institutional investors and hedge funds own 15.25% of the company’s stock.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.